ESC Professional Premium Access

Comparison of the antiarrhythmic potential of doxapram and its metabolite ketodoxaparam

Congress Presentation

About the speaker

Mr Manuel Kraft

University hospital Heidelberg, Heidelberg (Germany)
0 follower

7 more presentations in this session

The use of warfarin as part of antithrombotic strategy after transcutaneous aortic valve replacement is not associated with better medium-term outcomes

Speaker: Doctor J. Naser (Rochester, US)

Thumbnail

Direct oral anticoagulants compared to vitamin K antagonists for the treatment of left ventricular thrombi

Speaker: Doctor H. Morgan (London, GB)

Thumbnail

Frailty and outcomes in octogenarians with atrial fibrillation treated with edoxaban: ESCAPE study

Speaker: Doctor G. Denas (Padova, IT)

Thumbnail

Oral anticoagulant therapy and decline of kidney function in elderly patients with non-valve atrial fibrillation: real world evidence data

Speaker: Doctor G. Severini (Catanzaro, IT)

Thumbnail

Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding

Speaker: Doctor M. Hozman (Prague, CZ)

Thumbnail

Access the full session

Challenges in cardiovascular pharmacotherapy in patients who are older or with comorbidities

Speakers: Mr M. Kraft, Doctor J. Naser, Doctor H. Morgan, Doctor G. Denas, Doctor G. Severini...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb